Answers are grounded in this paper and cite their sources.
Mitochondria-targeted nanomedicines are increasingly viewed not only as organelle-seeking drug carriers, but also as bioactive materials that regulate mitochondrial function and tumor cell fate. By modulating membrane potential, redox homeostasis, calcium flux, bioenergetic metabolism, and apoptosis signaling, these systems can translate subcellular delivery into organelle-level therapeutic bioactivity. Yet their translation is constrained by a persistent design conflict: the cationic, lipophilic, or membrane-active features that promote mitochondrial affinity may also compromise systemic stability, biointerface safety, and normal-cell mitochondrial function. This review reframes mitochondria-targeted cancer nanomedicine as a bioactive-materials design problem. We distinguish mitochondrial localization, stimuli-regulated activation or release, and post-delivery mitochondrial modulation as three separate design functions, and evaluate representative direct-targeting, stimuli-responsive, externally activated, and theranostic platforms according to material architecture, biointerface behavior, organelle bioactivity, and translational bottlenecks. Finally, we summarize design rules for decoupling targeting from activation, engineering safer biointerfaces, validating triggers under physiologically relevant conditions, and simplifying multifunctional platforms for scalable translation. This framework may guide the development of safer and more controllable mitochondria-targeted bioactive materials for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: